Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret
Fierce Pharma
MARCH 10, 2023
Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret kdunleavy Fri, 03/10/2023 - 10:22
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Fierce Pharma
MARCH 10, 2023
Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret kdunleavy Fri, 03/10/2023 - 10:22
Fierce Pharma
OCTOBER 2, 2023
Even as Biogen weighs strategic options for its biosimilars unit, the group is celebrating an industry first. | The exact launch timing of the biosimilar remains unclear, but Roche said it expects competition to kick off in the second half of 2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 1, 2023
Imfinzi faces Keytruda competition in biliary tract cancer Phil.Taylor Wed, 01/11/2023 - 18:27 Bookmark this
European Pharmaceutical Review
SEPTEMBER 4, 2023
to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.
European Pharmaceutical Review
OCTOBER 14, 2022
Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. Seven more are expected to be launched in 2023. A rise in savings per quarter was recognised in this year’s data.
Fierce Pharma
JULY 11, 2023
With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely. With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely.
Healthcare Success
DECEMBER 6, 2022
In this blog, I share nine healthcare marketing trends you need to embrace in 2023 to remain competitive in today’s ever-changing healthcare marketplace. 9 Healthcare Marketing Trends 2023. Competition from Retail and Telehealth Disruptors Continues to Intensif y. Focus on these key audiences to stay competitive: a.
pharmaphorum
JANUARY 24, 2023
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.
European Pharmaceutical Review
AUGUST 21, 2023
For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 trillion in the Q1 of 2023 to $3.56 trillion in Q2 2023. Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1
LEVO Health
JANUARY 31, 2023
Therefore, it is essential to become familiar with the role SEO strategy plays in healthcare marketing and healthcare SEO best practices that should be employed in 2023 to create a successful digital marketing plan. Keywords that are too general will lead to more competition and a less targeted audience.
PM360
SEPTEMBER 21, 2023
Jeff Casberg, MS, RPh, Senior Vice President of Clinical Pharmacy at IPD Analytics, a managed care and pharmaceutical consultancy, highlighted a wide range of 2023 key events that will affect managed care professionals by the end of the year. This product is expected to have three generic launches in 2023.
European Pharmaceutical Review
JANUARY 10, 2023
Clarivate Plc has released its Drugs to Watch 2023 report — among 70 of the drugs highlighted, including potential blockbuster drugs, the majority were revealed to be personalised medicines. The report offers predictive analysis of drugs entering the market or launching key indications in 2023. Drug development in 2023 and beyond.
pharmaphorum
JANUARY 9, 2023
This Nine for 2023 three-part series will argue that, this year, the future-facing Janus prediction of unprecedented and transformative change is true. However, the pandemic is only one of the often deep-rooted forces that will come together in 2023 to exert transformative pressure on healthcare.
European Pharmaceutical Review
JANUARY 9, 2023
Record levels of deal-making Firepower, a company’s capacity to do M&A based on the strength of its balance sheet, is available for the life sciences sector, according to EY’s 2023 M&A Firepower report. M&A predictions for 2023. Global M&A activity in 2022.
LEVO Health
DECEMBER 20, 2022
As 2023 approaches, there are several strategies you can adopt to improve your healthcare marketing efforts and grow your practice. Adopting the following six marketing strategies may help you stay competitive, bring in new patients, and grow your practice substantially. 6 Medical Marketing Strategies to Adopt in 2023.
pharmaphorum
JANUARY 16, 2023
The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023. Innovation will power the market.
pharmaphorum
JANUARY 27, 2023
It’s wise advice from the “Sage of Omaha”; indeed, one highly respected financial newspaper began its 2023 predictions by conceding that it had been wrong on five major counts for 2022. In any case, there is only so much that companies can do on their own – which brings us to the third likely trend for 2023. The impact is two-fold.
European Pharmaceutical Review
FEBRUARY 7, 2023
A wave of important legislative changes is anticipated in the EU in 2023 making this year one of the biggest for the EU regulatory landscape governing the life sciences industry in recent times. As a key priority action under the ACT EU initiative, EU regulators plan to establish a multi-stakeholder platform (MSP) in 2023.
Star OUTiCO
NOVEMBER 30, 2022
January is one of the busiest recruiting times, so starting your hunt this month could mean lower competition and possibly improve your odds of securing your dream job. Reassess ahead of 2023. The post Top tips for finding a new job in 2023 appeared first on Star OUTiCO.
Copyright Clearance Center
MAY 16, 2023
May 16, 2023 – Danvers, Mass. – Nicknamed the “Stevies” for the Greek word meaning “crowned,” the competition receives over 12,000 entries each year from organizations in 70 countries. Nicknamed the “Stevies” for the Greek word meaning “crowned,” the competition receives over 12,000 entries each year from organizations in 70 countries.
pharmaphorum
JANUARY 5, 2023
As Chancellor of the Exchequer Jeremy Hunt said: “I want British firms to lead the world in turning fantastic science into new products and services – and we need to make sure government is doing everything we can to encourage innovation and competition.”. The post It’s time for more tech and biotech innovation in 2023 appeared first on.
European Pharmaceutical Review
JANUARY 11, 2024
billion, so biosimilar competition could significantly expand patient access to this biologic therapy within the fields of gastroenterology, dermatology, and rheumatology, according to STADA and Alvotech. The EU ustekinumab market is worth €2.5 In this region, STADA already has six biosimilars approved in this market.
Contrarian Sales Techniques
DECEMBER 31, 2023
Reflecting on 2023 2023 has been a year like no other. Highlights of the Year 2023 has been a transformative year in the world of sales, marked by significant advancements and innovations. The Power of Adaptability : If there's one thing 2023 has taught us, it's the importance of adaptability in sales.
European Pharmaceutical Review
NOVEMBER 30, 2023
Cell and gene therapy industry in 2023 According to data from the GMP Manufacturing Survey, in the past year: “There is an increase in the number of manufacturing organisations and the number of licensed facilities has remained stable. The 2023 data found that the split for bioprocessing roles was 57 percent.
PM360
APRIL 7, 2023
However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Expect the nine competitors to explore Kotler’s 4Ps of Marketing to gain share in this lucrative and competitive marketplace.
World of DTC Marketing
MARCH 17, 2021
Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. sales until at least 2023 because 257 patent filings stand in the way. In fact, Richard Gonzalez, C.E.O.
Clarify Health
NOVEMBER 15, 2021
By 2023, available annual profit pools will range from $11 billion to $13 billion, making Medicare Advantage the single biggest driver of profit growth for health care insurance providers ¹. For one national health plan, the strategy to improve and expand their Medicare Advantage networks was built upon meeting competitive overlap targets.
Clarivate
DECEMBER 19, 2022
For 2023 Medicare Advantage open enrollment, the United States’ largest retailer will begin a 10-year partnership with the nation’s largest insurer. The partnership dovetails with Walmart Health’s plans for 15 new Florida clinics across the Jacksonville, Orlando and Tampa markets by the end of 2023. MA national enrollment.
pharmaphorum
SEPTEMBER 15, 2022
The competition authorities in Switzerland said this morning they have carried out a raid on a pharma company – now confirmed to be Novartis – as part of an investigation into a “possible unlawful use of a patent to reduce competitive pressure.”
European Pharmaceutical Review
OCTOBER 10, 2023
The current Voluntary Scheme is due to end in December 2023. Unprecedented high payment rates in 2022 and 2023 have had a demonstrable impact on our ability to operate sustainably in the UK. Without a new deal agreed, all branded medicines sales will, for the first time, be subject to the statutory scheme, ABPI warned.
pharmaphorum
AUGUST 17, 2022
The latest life science competitiveness indicators (LSCIs) were published by the Office of Life Sciences (OLS) in July 2022. Indicators from the 2000s were captured in the Pharmaceutical Industry Competitiveness Task Force (PICTF) Indicators. The post UK life science competitiveness indicators 2022: measuring what matters most?
European Pharmaceutical Review
NOVEMBER 30, 2023
The company stated that based on the IQVIA’s 2022 report: The impact of biosimilar competition in Europe , as of 2022 “the cumulative savings at list prices from the impact of biosimilar competition in Europe reached over €30 billion. Furthermore, since the launch of biosimilars these provided nearly 4.5
European Pharmaceutical Review
APRIL 11, 2024
percent CAGR between 2023 and 2032. This has resulted in “increased competition and price pressure, driving the growth of the biosimilar market”. The latter of which is important in “gaining a competitive advantage”, the author noted. million by 2032, at 17.6
MedReps
JANUARY 30, 2023
If you know how to prepare and get ahead of your competition, reaching your goals will be that much easier. Medical Sales Trends to Watch Out For in 2023 If you want to know what the future holds and create some forward-thinking sales goals, then check out these medical sales trends to watch out for in 2023.
Clarify Health
JUNE 29, 2023
Ideon will power Clarify Networks’ competitive intelligence software module with national insurance network data across commercial, Affordable Care Act (ACA), and Medicare Advantage (MA) markets to empower health plans to gain valuable insights into their competitors’ networks.
European Pharmaceutical Review
OCTOBER 4, 2023
Sandoz to move headquarters to Basel, Switzerland Completion of the spin-off on the 4 October 2023 marks “a new era for Sandoz as an independent company” noted Sandoz’s Board Chairman, Gilbert Ghostine. To prepare for the separation, Sandoz stated in June that its headquarters would transfer to Basel, Switzerland.
Spotio
JUNE 13, 2023
However, some sales leaders are now using leaderboards to encourage healthy competition in their teams and reward sales reps who hit their goals. Having a team leaderboard that’s visible to the entire team is the perfect way to create some healthy in-house competition amongst your sales reps.
European Pharmaceutical Review
JULY 21, 2023
Supporting European biosimilar development Continued investment in biosimilars The planned financing builds on Sandoz’s announced investment in March 2023 of $400 million in a new biologics manufacturing plant in Lendava, Slovenia. This was the largest-ever international private-sector investment in the country, according to the company.
Spotio
FEBRUARY 6, 2023
In this post, we’ll talk about what sales enablement is and why it’s important, then we’ll share our list of the 62 best sales enablement tools available in 2023. Aloware Sales teams tend to adapt to newer technologies including sales tools that can cope with the increasing competition across various industries over time.
European Pharmaceutical Review
JANUARY 29, 2024
According to Medicines for Europe, the Munich District Court’s Supplementary Protection Certificate (SPC) manufacturing waiver , issued in Germany in October 2023, is “in conflict” with the objectives of the waiver. The organisation and its members are “strongly concerned” by the court’s first judgement of the waiver.
Clarivate
DECEMBER 18, 2023
As 2023 comes to a close , make sure you don’t miss out on the timely insights from Clarivate , created to help IP legal teams plan for the rapidly changing industry. As IP legal teams strategically navigated 2023 Clarivate created resources to help, backed by insights from industry experts.
Spotio
JULY 25, 2023
Source ) Alignment between sales and user intent Understanding the customer journey is a critical aspect of B2B sales, especially in a highly competitive field. The B2B customers of today have greater access to information online and offline – and they’re putting it to good use. 9-Step B2B Sales Process Now let’s see how to sell B2B.
Pharmaceutical Technology
MAY 11, 2023
The global pharma industry experienced a 9% drop in social media posts on internet of things in Q1 2023 compared with the previous quarter, with the highest share accounted for U.S. Centers for Disease Control and Prevention had the most mentions of internet of things in Q1 2023. Buy the report here.
Pharmaceutical Technology
MAY 29, 2023
The global pharmaceutical industry experienced a 17% rise in company filings mentions of blockchain in Q1 2023 compared with the previous quarter, with the highest share accounted for by Bayer, according to GlobalData’s analysis of over 60 pharmaceutical company filings. The overall index for blockchain in Q1 2023 was 74.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content